Market Research Blog – Page 15460 – New Product Development

Home Sleep Screening Devices Market Expanding at a healthy 8.5% CAGR, the market size is projected to total US$ 5.1 Bn by 2028

[290 Pages Report] Sales in the global Home Sleep Screening Devices Market are slated to top US$ 3.1 Bn in 2022. Expanding at a healthy 8.5% CAGR, the market size is projected to total US$ 5.1 Bn by 2028.

According to the latest research by Future Market Insights (FMI), global sales of Home Sleep Screening Devices exceeded the revenues worth US$ 2.3 billion in 2018. Toward 2019, FMI expects the revenue to observe robust increase by around 7%. According to the report, a majority of revenue through sales of home sleep devices will be generated by retail stores, the most preferred distribution channel for home sleep screening devices manufacturers, followed by the online sales segment.

In terms of revenue, the wearable sleep screening devices account for the revenue share of over 65% in the overall home sleep screening devices market. However, the increasing affordability and adoption of non-wearable devices for continuous sleep tracking without physical contact with the device is estimated to fuel the growth of the non-wearable home sleep screening devices segment in the near future.

Despite the fact that the rates of insurance reimbursement for home sleep studies are low, the convenience and portability offered by these devices compensate for the lack of reimbursement. A growing trend of using wearables as lifestyle devices is facilitating the demand for home sleep screening devices, and this is among the factors boosting the revenue generation of the home sleep screening devices market.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-8715

Prevalence of Sleep Related Disorders & Rising Number of Manufacturing Players Accelerating Market Reach of Home Sleep Screening Devices

The growing demand for sleep studies with home sleep screening devices can be attributed to the growing prescription numbers for home sleep tracking. Sleep disorders are affecting a large pool of population, which has boosted the awareness about these disorders and other related ailments. Increase in the prevalence of sleep disorders has led to an expansion of private care centres and hospitals. These sleep centres have increased awareness among people about the importance of tracking sleep patterns for better sleep. This is driving the usage of home sleep screening devices for sleep disorder cases, and subsequently increasing the revenue generation of the home sleep screening devices market.

Increasing number of manufacturers in the home sleep screening devices landscape and growing awareness among patients about sleep-related disorders will fuel the demand for home sleep screening devices across the globe. There has been a consistent increase in the number of local manufacturers of sleep tracker systems, as well as the availability of different types of trackers such as wristbands, headbands, tracker masks, and ring devices. This enables customers to choose from a range of products depending on the data they want to analyze and the type of wearable preferred by them, based on which they can opt for a product based on their affordability as well as medical feasibility. This is majorly contributing to the growth of the home sleep screening devices market.

Queries Regarding Report, Ask an Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-8715

Advancing Sleep Tracking Technology to Uplift Sales Potential of Sleep Screening Devices

The technology utilised in home sleep screening devices is based on the mapping of the REM sleep, heal rate, respiration patterns, and deep sleep. However, new home sleep screening devices are incorporating the same technology as the one used in Actigraphy and polysomnography devices. The growing trend of utilising a sleep tracker as a lifestyle accessory is estimated to promote the growth of the home sleep screening devices market.

Technological advancements in smart home sleep screening devices have led to the creation of hybrid devices that not only track activity, but also track sleeping patterns. These smart home sleep screening devices are capable of tracking fitness aspects such as the distance walked, calories consumed, heart rate monitoring, and can also track sleep patterns such as deep & light sleep and REM.

For instance, Fitbit, Inc.’s product Fitbit Ionic tracks fitness/activity as well as sleep patterns. It can record the REM, deep & light sleep, as well as provide tips for efficient sleeping patterns based on an individual’s lifestyle. Similar technological trends are estimated to eliminate the factors restraining the growth of the home sleep screening devices market.

The Consumer Electronics Association has collaborated with The National Sleep Foundation and formed “The Wearable Sleep Monitoring Equipment Group,” which is aimed at boosting the development of sleep technologies. This is also expected to improve the quality of wearable home sleep screening devices to ensure better data collection and storage. The introduction of certain new advancements and technologies are expected to create growth opportunities for the home sleep screening device market.

The report tracks some of the key companies operating in the home sleep screening devices market, which include

Fitbit, Inc.
Koninklijke Philips N.V.
Huami Corporation
Fossil Group, Inc.
Garmin Ltd.
Huawei Technologies Co., Ltd.
ResMed Inc.
Responsive Surface Technology, LLC
Simmons Bedding Company LLC.

Buy Industry Research Report: https://www.futuremarketinsights.com/checkout/8715

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/

Sennosides Market Industry Analysis, Opportunities, Technology, Demand, Top Players and Growth Forecast 2030

Sennosides Market OverviewSennosides s i.e. the Senna glycoside or Senna is a drug used for the treatment of constipation and helpful in emptying the large intestine in surgery. The drug is administered by the oral or rectum route.

It shows immediate therapeutic action when administered through the rectum route and it takes twelve hours when administered by the oral route. Sennosides invigorates peristalsis and rises faecal water substance to expand motility of defecation through the large intestine.

Sennosides is the FDA-approved OTC laxative which is used to treat constipation and also helpful in cleaning the bowel before a colonoscopy. Additionally, it is used in irritable bowel syndrome, haemorrhoids, rectal surgery, weight loss & anal fissures.

The COVID-19 situation has a positive impact at the sennosides market, i.e. the lockdown & restricted movements of the people has made changes in their eating habits including resting patterns with changing lifestyle.

All these factors led to disturbance of the normal routine of the person which is initiating with the problems of gastrointestinal disorders that is propelling the growth of th3e sennosides market.

Sennosides Market: Drivers and RestraintsIncreasing prevalence of gastrointestinal disorders, changes in lifestyle, dietary habits, increasing surgeries and high population rate are the driving factors responsible for the growth of the sennosides market. Moreover, the hectic schedule & changes in eating patterns i.e. irregular timings of food, contaminated foods, and junk food led to gastrointestinal disorders which are fueling the growth of the sennosides market.

To remain ‘ahead’ of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-12887

Meanwhile, rising awareness of therapeutic benefits and lack of serious complications are boosting the growth of the market. On the contrary adverse effects like stomach pain, headache & nausea is restraining the growth of the market.

Aside from this, the drug is contraindicated for the utilization in patients suffering from diarrhoea or in pregnancy.

Sennosides Market: OverviewSennoside A is mostly utilised as compared with sennosides B as it acts in the laxatives, which has demonstrated viable results in repressing the ribonuclease H (RNase H) action of human immunodeficiency infection (HIV) invert transcriptase 1.

Thus due to increased utilization of sennosides A is boosting the growth of the sennosides market. Moreover, it is mostly used in the pharmaceutical industry due to the increasing prevalence of gastrointestinal disorders and surgeries.

While the sennosides are widely used in the preparation of cathartics & laxatives. Meanwhile, it is found in the form of tablets as the oral route of drug administration is the most conveyance form of drug administration. Thus increasing prevalence of gastrointestinal disorders is providing a lucrative growth opportunity during the forecasted period.

Sennosides Market: Regional Wise OutlookGeographically, the Sennosides market is divided into seven regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, China, Japan & the Middle East and Africa. Asia-Pacific is expected to dominate the global Sennosides market followed by North- America & Europe.

Asia-Pacific is dominating the global Sennosides market due to the increasing prevalence of gastrointestinal disorder. As the population of developing countries (India & china) are higher, the incidences of GIT disorders are increasing amongst the population owing to the hectic schedule, lifestyle changes, and changes in dietary habits (junk food).

Moreover, most of the people are consuming it for increasing the metabolism of the food along with the health benefits. Moreover, the lack of serious adverse reactions is the major factor in boosting the growth of the sennosides market. Thus, all these factors are propelling the sennosides regional market.

Rapid development & Advancements along with the changing snacking tendency is going to offer a lucrative opportunity for the growth of sennosides market at North America during the forecasted period.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-12887

Sennosides Market: Key Market ParticipantsThe key participants operating in the global Sennosides market identified across the value chain include

Pai pharmaceutical Associates, Inc.
Madaus
NOW Health Group Inc. (Now Foods)
Changsha Vigorous-Tech
Vital Laboratories
Health and Herbs
Alchem International
Shaanxi Hongda Phytochemistry
Nutra Green Biotechnology Co. Ltd
Elixir Natural Labs
Shaanxi Jintai Biological Engineering
Alps Pharmaceutical
Shashi Phytochemical Industries
Shaanxi huadong Biological Technology Co. Ltd.
Kattwiga
SAB Herbals & Nutraceuticals
Santen
Apex International
Xi’an Wonderful Herb Biotechnology
Wuhan Vanz Pharm
Xi’an Lyphar Biotech
Kothari Phytochemicals
SHASHI PHYTOCHEMICAL INDUSTRIES.

The players working in the worldwide Sennosides market are concentrating on the drug discovery i.e. by combining the drug with various other extracts for the development of new therapeutic medication which would be helpful in prevention & cure of various disorders.

The Report Covers Exhaust Analysis On

Sennosides market Segments
Sennosides Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain

Regional Analysis Includes

North America (U.S., Canada)
Latin America (Mexico. Brazil)
Western Europe (Germany, Italy, France, U.K, Spain)
Eastern Europe (Poland, Russia)
Asia Pacific (India, China ASEAN, Australia & New Zealand)
Japan
The Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

Report Highlights

Detailed overview of the Fast-moving consumer goods market
Changing Sennosides market dynamics in the industry
Below the Sennosides market -depth market segmentation
Historical, current, and projected market size in terms of volume and value
Below the Sennosides market recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint

For in-depth competitive analysis Buy Now – https://www.futuremarketinsights.com/checkout/12887

Sennosides Market: Segmentation

The global Sennosides market has been segmented based on product form, type, application, end-user and geography.

Based on the type :

Sennosides B
Sennosides A

Based on the product form :

Tablet (chewable, sugar-coated)
Liquid (syrup, extract)
Powder
Others

Based on the end-user :

Pharmaceuticals Industry
Food Industry
Research laboratories
Cosmetics
Others

Based on the application :

Cathartics & Laxatives
Nutraceuticals
Surgery
Others

Mucus Clearance Devices Market are slated to top US$ 595.2 Mn in 2022

[191 Pages Report] Sales in the global Mucus Clearance Devices Market are slated to top US$ 595.2 Mn in 2022. Expanding at a healthy 6.1% CAGR, the market size is projected to total US$ 847.0 Mn by 2028.

An in-depth review of growth drivers, potential challenges, unique trends, and opportunities for market participants equip readers to fully comprehend the overall landscape of the mucus clearance devices market. The report on mucus clearance devices market also covers analysis of key regions and countries of particular interest which are anticipated to become frontrunners or remain laggards over the forecast period. The report covers a historical analysis of the mucus clearance devices market from 2013 to 2017 and provides forecasts from 2018 to 2028 in terms of volume in thousands units and revenue in US$.

Request a Sample of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-9416

This report on mucus clearance devices market has been broken down into different chapters to enhance clarity and provide context. A brief executive summary at the beginning of the report consists of some of the key findings of the study on mucus clearance devices market, as well as market estimates and growth rates for important segments. The following chapter presents the definitions and scope of the study, as well as the coverage in terms of the way the mucus clearance devices market is structured.

Subsequently, the chapter on market background presents the evolution of mucus clearance devices, potential drivers and restraints impacting the mucus clearance devices market as well as an explanation of the factors considered important to develop forecasts and estimates. Further, the report on mucus clearance devices market highlights the key success factor affecting the growth of the market. This section explains about the global impact of chronic disease and aging, mucus clearance therapy and techniques along with key regulatory scenario and list of FDA approved mucus clearance devices.

The next chapter of report on mucus clearance devices provides the volume analysis and forecast for the period of 2018-2028. Following this further chapter highlights the pricing analysis along with price point variations between different regions and products, including pricing forecasts. Succeeding set chapter provide the detail value analysis and forecast mucus clearance devices market by product type, indication, end user and region. The next set of chapters provide region-wise analysis and forecasts of the mucus clearance devices market, covering vital aspects of the market in North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa. After the completion of regional analysis, tier structure analysis and company share analysis for 2017 is highlighted in the next chapter. Following that subsequent chapter feature the competition dashboard and company profiles.

A demand side approach is used to estimate the market value for mucus clearance devices. Initially, the prevalence of cystic fibrosis, COPD and bronchiectasis in top 25 countries is analysed with help of secondary research. Additionally, the adoption of different type of mucus clearance devices among the patient for treatment of this diseases is analysed through secondary and primary research. The adoption of mucus clearance devices among this patient has provided the volume for the base year.

Moreover, prices of mucus clearance devices have been obtained from manufacturers, distributors, and wholesalers at a country-level to calculate the average selling price of different type of mucus clearance devices. The volume is multiplied with the average selling price to estimate the mucus clearance devices market value for the base year. A top down analysis approach is used to cross validate the market value of mucus clearance devices.

An exhaustive list of manufactures and their mucus clearance devices is prepared based on secondary research. The revenue generated by each manufacturer from mucus clearance devices is tap down. This information is further validated with rigorous primary research (including interviews, surveys, in-person interactions and the viewpoints of analysts) and secondary research (including verified paid sources, authentic trade journals and resourceful databases).

Global Mucus Clearance Device Market: Segmentation:

Analysis by Product Type

HFCWO Devices
OPEP Devices
MCA Devices
IPV Devices
PEP Devices

Analysis by Indication

Cystic Fibrosis
COPD
Bronchiectasis
Others

Request for Report Ask A Question @ https://www.futuremarketinsights.com/ask-question/rep-gb-9416

Analysis by End User

Homecare Settings
Hospitals
Specialized Clinics
Rehabilitation Centers
Ambulatory Surgical Centers

Analysis by Region

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa

About Future Market Insights (FMI)

Neurovascular Guidewires Market is projected register CAGR of 4.0% during the forecast period 2022-2028

[269 Pages Report] The global Neurovascular Guidewires Market is projected register CAGR of 4.0% during the forecast period 2022-2028. Increasing demand for straight tip guidewires for minimally invasive spine and cervical surgeries is accelerating the growth in the market.

According to a new research study of Future Market Insights,

Straight tip guidewires, with a current share of more than a third of the total market value, will retain the dominant position in neurovascular guidewires market through 2028.
Aneurysms and intra-and extra-cranial angioplasty reflect highest applicability of neurovascular guidewires.
Hospitals, though anticipated to reflect limited investment opportunities in the neurovascular guidewire market, will remain the leading end-use segment with the maximum share in terms of revenue generation.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-3121

The Increasing Number of Neurovascular Disease Treatment Alternatives

Neurovascular guidewires, among the latest innovations in the neurovascular disease treatment landscape, has been pushing the number of neurovascular surgeries since introduction. This according to the report will remain a key factor sustaining demand for neurovascular guidewires in the global market over the coming years.

As the advent of technology used in neurovascular surgeries has significantly increased the number of treatment options for neurovascular diseases, the treatment by using neurovascular guidewires is gaining ground rapidly owing to the relatively lower risk associated with surgical treatment, over conventional surgeries. The usage of guidewires is the mainstay for neurovascular therapy, along with new technologies such as coating-based guidewires, which has contributed substantially to the treatment options for complex lesions that are treated surgically.

Favorable Reimbursement Scenario & Government Support

The growing prevalence and incidence of cerebral infarction, aneurysm, and stroke is projected to fuel the demand for neurovascular guidewires. Growth in the number of patients suffering from ischemic stroke across the world is also estimated to boost the adoption of neurovascular guidewire and contribute to the growth of the global neurovascular guidewire market during the forecast period.

Similarly, increasing incidence of arteriovenous malformations is also contributing to growth in the demand for neurovascular guidewires. The increasing prevalence of intracranial and extracranial angioplasty is another factor that is expected to drive the neurovascular guidewires market.

Buy this report @ https://www.futuremarketinsights.com/checkout/3121

Neurovascular guidewires are effective and safe devices in neurovascular intervention procedures for patients suffering from neurovascular diseases. Modifications in reimbursement policies are encouraging the number of outpatients in developed countries. Government initiatives and local reimbursement policies pertaining to the usage of neurovascular guidewires are also expected to boost the neurovascular guidewire market over the forecast period.

FMI’s report tracks some of the key companies operating in the neurovascular guidewire market, which include Boston Scientific Corporation, Medtronic, Penumbra Inc., Stryker, Asahi Intecc Co. Ltd, Integer Holding Corporation, Cordis Corporation, CONMED Corporation, phenox GmbH, and Integer Holding Corporation, among others.

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/customization-available/rep-gb-3121

About Future Market Insights (FMI)

Venous Thromboembolism Treatment Market is expected to exceed US$ 1.53 Billion by 2022

[243 Pages Report] The global demand for venous thromboembolism treatment market is likely to grow steadily over the forthcoming years. As indicated by a recent Future Market Insights (FMI) study, the market revenues will observe approximately 3.7% CAGR between 2022 and 2029.

More than 3/5^th of treatment demand is underpinned by deep venous thrombosis, according to the report. Catheter-directed thrombolysis devices and percutaneous thrombectomy devices, collectively account for more than half of the global revenues represented by the venous thromboembolism treatment market.

Venous thromboembolism treatment involves segmented pneumatic compression pumps without gradient, segmented pneumatic compression pumps with calibrated gradient, lower pneumatic compression sleeves, non-segmented pneumatic compression pumps permanent inferior vena cava filters, retrievable inferior vena cava filters, embolectomy balloon catheters, percutaneous thrombectomy devices, catheter-directed thrombolysis (CDT) devices and upper pneumatic compression sleeves. Based on the disease indication, deep vein thrombosis is expected to hold a prominent share in the overall venous thromboembolism treatment market.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-1341

Poor Reimbursement Scenario Against High Treatment Costs to Restrict AdoptionSeveral factors are impacting the overall growth of the venous thromboembolism treatment market. The first and the most important factor driving the venous thromboembolism treatment market is the increasing prevalence of venous thromboembolism disease. Other factors, such as the increasing retrieval rate of vena cava filters, increasing healthcare awareness, presence of favourable reimbursement policies, and increasing geriatric population, are also responsible for the growth of the venous thromboembolism treatment market.

Apart from the driving factors of venous thromboembolism treatment market, there are few factors that are likely to hinder the overall growth of the venous thromboembolism treatment market. The high cost associated with venous thromboembolism treatment therapy, poor reimbursement for some of the treatment devices, and poor insurance support are among the major factors that are expected to hamper the growth of the venous thromboembolism treatment market.

Drug-based Treatment Witnessing Traction across EuropeAlthough increasing preference for drug-based venous thromboembolism treatment is highly likely to hinder the growth of the market, new-generation drugs, including non-Vitamin K antagonist oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, apixaban, and edoxaban, are estimated to boost the adoption rate of venous thromboembolism treatment due to increased efficacy. However, there are regional variations to this trend.

North America is expected to be a prominent region in the global venous thromboembolism treatment market because of the presence of a well-developed healthcare infrastructure and numerous technological advancements in the region. The increasing prevalence of venous thromboembolism is also responsible for the boosting the growth of the North America market. Treatment using mechanical and interventional prophylaxis systems is expected to be increasingly adopted in the North American region during the forecast period. In addition, drug-based treatment is expected to gain popularity in the European region, which is expected to subsequently decrease the usage of mechanical and interventional treatments in the region.

On the other hand, increasing per capita healthcare expenditure is one of the macroeconomic factors that is likely to boost the market. Nowadays, certain changes in the socio-economic scenario can also lead to significant growth in the venous thromboembolism treatment market.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-1341

Tier 1 Players Account for Nearly 35% Market Revenue ShareSome of the key manufacturers of venous thromboembolism treatment are mainly focusing on innovating and launching new and advanced products. Major players in the venous thromboembolism treatment market are focusing on collaborations and acquisitions. For example, venous thromboembolism treatment is majorly adopted by hospitals, catheterisation laboratories, and ambulatory surgical centres. Hospitals are expected to hold a significant revenue share in the venous thromboembolism treatment market.

The report tracks some of the key companies operating in the venous thromboembolism treatment market such as ArjoHuntleigh AB, AngioDynamics, Cardinal Health Inc., BTG International Ltd., Stryker Corporation, DJO Global Inc., EKOS Corp, and Teleflex Inc., Boston Scientific Corp. There are several other companies operating in the venous thromboembolism treatment market. AngioDynamics, Boston Scientific Corp., and Cardinal Health Inc. are expected to hold a prominent share in the venous thromboembolism treatment market. These tier 1 companies hold a share of approximately 35% in the venous thromboembolism treatment market.

Venous Thromboembolism Treatment Market by CategoryBy Product:

Non-Segmented Pneumatic Compression Pumps
Segmented Pneumatic Compression Pumps without Gradient
Segmented Pneumatic Compression Pumps with Calibrated Gradient
Upper Pneumatic Compression Sleeves
Lower Pneumatic Compression Sleeves
Permanent Inferior Vena Cava Filters
Retrievable Inferior Vena Cava Filters
Embolectomy Balloon Catheters
Percutaneous Thrombectomy Devices
Catheter-Directed Thrombolysis (CDT) Devices

By Disease Indication:

Deep Venous Thrombosis
Pulmonary Embolism

By End User:

Hospitals
Catheterisation Laboratories
Ambulatory Surgical Centers

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/1341

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

Mucopolysaccharidosis (MPS) Treatment Market is estimated to be worth around US$ 2.38 Billion in 2022

[220 Pages Report] A market study presented by FMI ‘ Mucopolysaccharidosis Treatment Market: Global Industry Analysis 2014-2021 and Opportunity Assessment 2022-2029,’ explains the significant factors influencing the current market structure.

According to research, the mucopolysaccharidosis treatment is still emerging, and different geographies have implemented standard treatment options for the condition. However, there is no universally accepted treatment pattern for mucopolysaccharidosis. Mucopolysaccharidosis falls under rare diseases, which is a complex, diverse, constantly evolving field, and there is a significant shortage of medical and scientific data related to it. Mucopolysaccharidosis treatment and diagnosis involves complex managing requirements, which include long-term care, rehabilitation support, and a continuous treatment plan.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-5880

Research Activities Uplift Stem Cell Therapy Application in MPS Treatment

In the present scenario, the drugs that are considered for mucopolysaccharidosis treatment, such as aldurazyme, naglazyme, vimizim, elaprase, mepsevii and hunterase, are the only regulated and recommended drugs present in the market. These drugs fall under enzyme replacement therapies, however, with present research initiatives for stem cell therapies, the latter is considered a prominent mucopolysaccharidosis treatment. Clinical research shows that stem cell transplantation covers a large area that is not covered with the more frequently recommended practice of enzyme replacement therapies, which changes the current market structure for mucopolysaccharidosis treatment, prioritising the latter.

Stem cell therapy is a therapeutic option for mucopolysaccharidosis patients suffering from a severe phenotype, as research shows the method can preserve neurocognition or can even help break the progressive neurodegeneration. The method is provided with strict selection criteria, which is followed by maintained regulations. Research shows that stem cell therapy as a treatment option is gaining popularity among healthcare professionals for mucopolysaccharidosis treatment, which can be attributed to the relation of its better reach towards a normal health condition for the patient.

Enzyme Replacement Therapy Remains Lucrative for Market Investors

As per further assessments of the mucopolysaccharidosis treatment market, it has been difficult to collect epidemiological data pertaining to rare diseases, especially mucopolysaccharidosis treatment, which is likely to impede the actual estimation of the economic burden associated with the condition. The cost estimation for each mucopolysaccharidosis treatment type is affecting and, in turn, creating a more vulnerable situation for the businesses and disrupting research & development activities for each company.

Enzyme replacement therapy is the most attractive segment for investors, however, the unavailability of reimbursement plans and precise treatment plans is encouraging most patient in developing regions to opt for symptomatic treatments instead of enzyme replacement therapy, which is still considered to be the standard mucopolysaccharidosis treatment.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-5880

Key Players Focus on Clinical Research of Treatment Models

The report segments the mucopolysaccharidosis treatment market into seven regions to elaborate on the regional trends pertaining to the treatment plan. Major players are focusing on increasing their market share in the Asia Pacific market through strategic collaborations with regional research institutes. There is a lack of awareness about rare diseases among the general public as well as in medical healthcare facilities in several emerging economies. According to a survey and industry report, it takes patients in the US an average of 7.6 years and patients in the UK an average of 5.6 years to actually receive a proper diagnosis. Moreover, it involves a team of healthcare professionals to actually get the right mucopolysaccharidosis treatment and diagnosis pattern for reported cases.

Manufacturers are in the process of introducing a considerable number of mucopolysaccharidosis treatment options, which are currently under clinical trials. An estimated 160 and above clinical trials are being performed for mucopolysaccharidosis treatment. Thus, ensuring that the manufacturers take this mucopolysaccharidosis treatment market to be lucrative and potential rich in terms of revenue. Medical research institutes play an important role in this particular market. They are expected to be the bridge between treatment plans and economical solutions for manufacturers, thus leaving an explicable and lucrative model for mucopolysaccharidosis treatment.

The mucopolysaccharidosis treatment market includes companies such as BioMarin Takeda Pharmaceutical Company Limited, Sanofi S.A., and Ultragenyx Pharmaceutical Inc. BioMarin accounts for a significant value share in the present mucopolysaccharidosis treatment market. The currently existing promising drug types are expected to face competition from emerging candidates. In addition the mucopolysaccharidosis treatment products of other companies, such as Sangamo Therapeutics, Inc., REGENXBIO Inc., Sarepta Therapeutics, Abeona Therapeutics, Inc., and others, are also in the pipeline.

Mucopolysaccharidosis Treatment Market by Category

Treatment

Enzyme Replacement Therapies
Stem Cell Therapies
- Bone Marrow Transplantation
- Umbilical Cord Blood Transplantation

Type of MPS

MPS I
MPS II
MPS IV A
MPS VI
MPS VII

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/5880

End User

Hospital
Specialty Clinics
Medical Research Centers
Home-infusion

Dialyzer Reprocessing Machines and Concentrates Market were valued US$ 967.4 Mn in 2018

According to the latest report published by Future Market Insights (FMI), sales of global dialyzer reprocessing machines and concentrates market were valued at US$ 967.4 Mn in 2018 and are expected to tread on an ever-increasing trajectory through 2028.

Dialysis continues to be highly preferred for effective treatment of chronic kidney diseases (CKD) among the geriatric population, thereby generating substantial demand for re-usable dialysis equipment. This, in turn, is foreseen to create revenue-generating opportunities for the companies operating in the dialyzer reprocessing machines and concentrates market.

Dialyzer Reprocessing Machines and Concentrates Market

North America Continues to Mark the most Significant Position in Market

According to the report, rising instances of renal disorders, such as end stage renal disease (ESRD) and chronic kidney disease (CKD), are among the key factors spurring growth of dialyzer reprocessing machines and concentrates market. Dialysis, being the most accessible treatment for kidney diseases, will thus continue to add to the overall importance of re-usable dialysis equipment. This, in turn, will create favourable grounds for adoption of global dialyzer reprocessing machines and concentrates market.

Get Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-9272

In 2015, it was estimated by the National Kidney Foundation in the US that approximately 468,000 ESRD patients are reported to be on dialysis in the US alone. North America will thus continue to be a prominent region in the global dialyzer reprocessing machines and concentrates market, followed by South Asia. In 2018, North America accounted for a revenue share of around 24% in dialyzer reprocessing machines and concentrates market, backed by a robust healthcare infrastructure.

India, Sri Lanka, and, Thailand on the other side are likely to emerge as potential countries brimming with prime opportunities for the companies operating in the dialyzer reprocessing machines and concentrates market.

According to the report, introduction of technologically advanced medical equipment all-aligned with the evolving healthcare models is further expected to boost the growth of dialyzer reprocessing machines and concentrates market. dialyzer reprocessing machines and concentrates enable automated cleaning and reprocessing of the dialysis units, unlike the traditional re-usable systems that required manual handling. As per the research study, dialyzer reprocessing machines provide immense scope for direct handling of the dialysis systems using automated digital reprocessors, which is an added advantage boosting popularity of dialyzer reprocessing machines and concentrates over the conventional systems.

The report opines that the end-users will continue to showcase marked preferences for hemodialysis concentrates among all other product types in the dialyzer reprocessing machines and concentrates market space. Hospitals are anticipated to lead in terms of adoption of dialyzer reprocessing machines and concentrates, followed by dialysis centres.

Key Manufacturers Emphasize Stronger Distribution Network for Better Regional Foothold

The dialyzer reprocessing machines and concentrates market report profiles few of the key companies operating in the global market space with robust product portfolios. Some of these key players in the dialyzer reprocessing machines and concentrates market include CURA Healthcare, MEDIVATORS Inc., Fresenius Medical Care, Baxter, Anjue Medical Equipment Co., Ltd., B. Braun Melsungen AG, Nipro Corporation, Cantel Medical, AIN MEDICARE SDN BHD and Rockwell Medical.

A majority of the regional players in the dialyzer reprocessing machines and concentrates market are focused on increasing their product reach and connectivity with the regional distributors of dialyzer reprocessing machines and concentrates. The dialyzer reprocessing machines and concentrates manufacturers are focused to strengthen their foothold in potential dialyzer reprocessing machines and concentrates markets such as India, China, Thailand, Bangladesh, and Argentina by expanding their sales and distribution channels across these countries.

Any Queries, ask an Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-9272

About Future Market Insights (FMI)

Medical Physics Market has been estimated to expand at a healthy CAGR of 6.4% over 2018-2028, and size in 2018 – Approximately US$ 3.5 Bn

According to the latest research by Future Market Insights (FMI), the global market for medical physics will exceed the valuation of US$ 6 billion towards the end of projection period.

Prominently driven by the growth of medical tourism sector and increasing expanse of diagnostics, the global revenue of medical physics market will reportedly thrive at a healthy over-6% CAGR during 2018-2028. Growing adoption of nuclear medicine has also been cited as an important factor responsible for a positive growth outlook anticipated for medical physics market.

However, the report also highlights that the insufficient availability of skilled workers and relatively poor healthcare infrastructure for medical physicist trainings in developing regional markets will continue to restrict penetration of medical physics in the long run.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-5274

The ‘Outsourcing’ Trend Is Creating Firm Base for Merger & Acquisition Strategies

With the consolidation of hospitals, there is an increasing need for larger firms in the medical physics market, with an intent to handle the outsourced services so as to contract with fewer services providers. The medical physics market is characterised by the presence of small independent companies, and there is a negligible number of large-scale operators. According to the report, this presents opportunities for private equity firms to enter the middle-market platform and scale-up their medium-scale operations to large-scale operations through the acquisition of smaller firms.

Other factors driving mergers and acquisitions in the medical physics market include increasing stringent regulations and an increasing number of owners looking to exit the medical physics business. Increasing stringent regulations have resulted in the inspection of a larger number of machines and associated elements. Several healthcare systems are incurring higher risks due to the increasingly stringent regulations. This opens opportunities for medical physics companies to ensure compliance and reduce operation cost by outsourcing. Furthermore, most of the medical physics firms are owned and operated by baby boomers who are about to retire from their medical physics business. For a majority of those medical physics service providers who are retiring, selling their business has been considered to be the most preferred option.

Preview Analysis Global Medical Physics Market Segmentaion by Modality (Diagnostic, Therapeutic); by Services (Accreditation Assistance, Performance Testing, Physics Testing, Radiation Dose Monitoring, Radiation Safety Training, Treatment Commissioning Services, Safety Surveys, Regulatory and Auditing Services, Others: https://www.futuremarketinsights.com/reports/medical-physics-market

Some of the other trends in the medical physics market include increased outsourcing by healthcare providers, increasing number of independent diagnostic imaging centres, and advancements & adoption of technology across the world.

Segmental Insights: Medical Physics Market

Diagnostic modality, driven by increasing adoption of diagnostic procedures such as PET, SPECT, CT, and MRI, will continue to account for more than 65% share of the total medical physics market value.
Based on services, accreditation assistance is slated to remain dominant, followed by safety surveys. The report anticipates physics testing and regulatory and auditing services to emerge highly potential.
Following hospitals, diagnostic imaging centers are likely to register significant adoption rate in the medical physics market through 2027.

The North American and European medical physics market will reportedly account for a majority of market value, according to FMI’s analysis on medical physics market. The report has attributed this dominance to rapid consolidation of healthcare facilities in these regions.

Some of the key players in the medical physics market include Krueger-Gilbert Health Physics, Inc., LANDAUER, Medical Physics Services, Medical Physics Services Consultants, Inc., Alyzen Medical Physics Services, Radiation Safety & Control Services, Inc., Upstate Medical Physics Services, Dade Moeller & Associates, Versant Medical Physics Services & Radiation Safety, Alliance Medical Physics Services LLC, West Physics Consulting, LLC, Associates in Medical Physics Services, Radiation Services, Inc., Jaeger Corporation, and Petrone Associates, LLC.

Buy Medical Physics Market Research Report @ https://www.futuremarketinsights.com/checkout/5274

More from FMI’s Healthcare, Pharmaceuticals and Medical devices Market Intelligence:

Hematology Diagnostics Market– Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2026
Allergy Immunotherapy Market– Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017-2025
Tattoo Removal Lasers Market– Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018-2028

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Contact Us

Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): + 44 (0) 20 7692 8790
Sales: sales@futuremarketinsights.com
Press Office: Press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/

RFID in Pharmaceuticals Market is envisaged to record a CAGR of over 8% through 2028

According to the study, such preventative measures against infiltration of counterfeit drugs are likely to have a positive economic influence on legitimate companies, who are now focusing on the deployment of anti-counterfeiting solutions. Focus of the organized players in the pharmaceutical sector to safeguard authenticity of their products, while creating moats for counterfeiters, will continue to favour growth of the RFID in pharmaceutical market.

Future Market Insights (FMI), in its new study, finds that the radio-frequency identification (RFID) in pharmaceuticals market was valued at over US$ 950 Mn in 2018, and is estimated to register a Y-o-Y growth at approximately 10% in 2019. Prospects remain remarkable for the RFID in pharmaceuticals industry, as efficiency-led actions of players continue to enhance the reliability and accuracy of their business operations.

The study finds that drug tracing system remains the most lucrative application of RFID in pharmaceutical industry, accounting for approximately 60% sales. Efforts of the FDA, in collaboration with pharmaceutical suppliers, to maintain a secure drug supply in the wake of rising counterfeit drugs prevalence, has encouraged the pharmaceutical industry to use RFID in combination with the electronic product code (EPC) for real-time tracking, tracing, and authentication of drugs.

To remain ‘ahead’ of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-9508

Chipless RFID Sales Remain Over 2X of Chipped RFID

According to the study, chipless RFIDs continue to gain robust attractiveness in the pharmaceutical industry, as they eliminate the hardware-related challenges associated with their chipped counterparts. Additionally, RFIDs without ICs allude at significant cost reduction of the component, in turn complementing their development and demand on a wide scale. However, complexities linked with designing and development of chipless RFID, such as data transmission and encoding, continue to sustain the demand for the chipped RFID to a certain extent. The study finds that sales of chipless RFID will remain over 2X that of the chipped RFID in 2019.

The study expects RFID reader to remain the core component in the RFID in pharmaceutical market, with growing focus of pharma suppliers on effective identification of products prior to their collection, storage and shipping. Gains in the RFID in pharmaceutical market will remain complemented by sales of RFID tags, with revenues in 2018 accounting for over one-third market share.

Adoption Remains High among Drug Manufacturers

Application diversity of RFID in pharmaceutical industry has led its adoption among a wide range of end-users that range from drug manufacturers and drug wholesalers, to hospitals and clinics. The report estimates drug manufacturers to account for leading shares of the RFID in pharmaceutical market, who are constantly emphasizing on ensuring the authenticity of their products in the market. Adoption is expected to witness high-growth among drug wholesalers and hospitals and clinics, which collectively account for over two-fifth share of the market.

The study states that North America will remain the leading market for RFID in pharmaceutical, with Europe following the suit. Supremacy of developed economies in the RFID in pharmaceutical market is significantly attributed to stringent standards & regulations implemented for serialization, and relative greater prevalence of OTC and generic drugs in these regions. Additionally, focus of players in developed markets remains strong on brand protection, and preventing packaging-related product recalls, which in turn augurs well for growth of the RFID in pharmaceutical market.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-9508

This FMI study also offers a long-term forecast of the RFID in pharmaceutical market for the period between 2018 and 2028. The RFID in pharmaceutical market is envisaged to record a CAGR of over 8% through 2028.

RADIO-FREQUENCY IDENTIFICATION (RFID) IN PHARMACEUTICALS MARKET TAXONOMYThe global gene editing tools market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

By Component

RFID Readers
RFID Tags
RFID Middleware

By Type

Chipped RFID
Chipless RFID

By Application

Drug Tracing System
Drug Quality Management
Others

By End Use

Drug Manufacturer
Drug Wholesalers
Hospitals and Clinics
Others

For in-depth competitive analysis Buy Now – https://www.futuremarketinsights.com/checkout/9508

Region

North America
Latin America
Western Europe
Asia Pacific Excluding Japan
Eastern Europe
Middle East and Africa
Japan

Viscosupplementation Market revenues are likely to reach USD 4 billion by the end of 2030

Global viscosuppplementation revenues are likely to reach USD 4 billion by the end of 2030, according to a new research by ESOMAR-certified firm Future Market Insights.

According to the study, a number of broader, and industry-specific factors will drive growth in this market, which has been relatively less impacted by the sluggishness induced by COVID-19.

As per the UN, by 2050, those aged 60 and above will account for over 20% of the global population. In other words, the UN says that by 2050 around 130 Mn people will contract osteoarthritis. These numbers point towards growth in the viscosupplementation market in the forecast period.

Covid-19 Pandemic: Viscosuppplementation Market Players Consolidating their PositionThe ongoing Covid-19 pandemic has compelled the market players to take a consistent path for the next two quarters. As it would take some time for the healthcare vertical to look through new product launches; the players are looking at ways to smoothen the supply chain as manpower has taken a hit.

Continuous innovations are expected to propel the growth of viscosupplementation market” says the FMI analyst

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-9509

Key Takeaways of Viscosupplementation Market Study

Three injection viscosuppplementation is expected to contribute for more than 55% of revenue share
Knee osteoarthritis is expected to gain around one-third of market share during the forecast period
North America is the highest revenue generating market due to scientific advancements and high adoption of viscosuppplementation

New Product Development to be the TorchbearerThe market players are into the innovation mode to strengthen their foothold in the viscosupplementation market. This competitive landscape is all set to create ripples all across the market. Some of the innovations are:

Fidia Pharma USA Inc., in 2019, introduced a HA (Hyaluronic Acid) based intra-articular viscosupplement called “TRILURON” to treat knee osteoarthritis. The treatments cycle involves 3 injections at weekly intervals.
Japan-based Seikagaku Corporation, in Mar 2019, launched an intra-articular single-injection viscosupplement called “HyLink” in Italy for treating knee osteoarthritis.
Recently, Gel-One Hyaluronate was approved as one of the injectable gels to treat osteoarthritis of knee. The pre-market clinical study reported no pseudosepsis (severe acute inflammatory responses).

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-9509

Want more insights?Viscosupplementation market, a new study from Future Market Insights, opines on the viscosupplementation from 2015 – 2019 and presents demand projections from 2020 – 2030 on the basis of; product types (single injection viscosupplementation, three injection viscosupplementation, and five injection viscosupplementation), application (knee osteoarthritis, hip osteoarthritis, shoulder osteoarthritis, and others such as elbow and ankle joint osteoarthritis), and end user (hospitals, ambulatory surgical centers, orthopedic clinics, retail pharmacies, and online sales) across seven prominent regions.

Viscosupplementation Market: SegmentationThe global viscosupplementation market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Product Type

Single Injection Viscosupplementation
Three Injection Viscosupplementation
Five Injection Viscosupplementation

Application

Knee Oseteoarthritis
Hip Oseteoarthritis
Shoulder Oseteoarthritis
Others

End User

Hospitals
Ambulatory Surgical Centers
Orthopedic Clinics
Retail Pharmacies
Online Sales

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/9509

Region

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa (MEA)